Vaccine Induced Seroreactivity Following Administration of ALVAC-HIV/AIDSVAX®B/E Identified by Common Anti-HIV Test Kits and Algorithms in Thailand

Akapirat S.Serti E.Pitisutthithum P.Nitayaphan S.Chariyalertsak S.Eamsila C.Panjapornsuk P.Kleebmontha A.Chantakulkij S.Tongchanakarn B.Savadsuk H.Dhitavat J.Gurunathan S.Sinangil F.Crowell T.A.Michael N.L.Robb M.L.Vasan S.O’Connell R.J.Mahidol University2025-10-122025-10-122025-10-01Open Forum Infectious Diseases Vol.12 No.10 (2025)https://repository.li.mahidol.ac.th/handle/123456789/112544Vaccine-induced seroreactivity (VISR) was evaluated in RV306 and was shown to vary markedly (0–32.5%) among 6 HIV diagnostic tests and 84 algorithms. Our data show that selecting the SD Bioline HIV-1/2 assay and algorithms which exclude the ImmunoComb®II Bispot and Alere™ Determine HIV-1/2 assays would almost eliminate VISR in RV306.MedicineVaccine Induced Seroreactivity Following Administration of ALVAC-HIV/AIDSVAX®B/E Identified by Common Anti-HIV Test Kits and Algorithms in ThailandArticleSCOPUS10.1093/ofid/ofaf5782-s2.0-10501760474223288957